Advertisement

Topics

Latest "GeneCentric Therapeutics" News Stories

16:13 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "GeneCentric Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about GeneCentric Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about GeneCentric Therapeutics for you to read. Along with our medical data and news we also list GeneCentric Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of GeneCentric Therapeutics Companies for you to search.

Showing "GeneCentric Therapeutics" News Articles 1–25 of 8,200+

Extremely Relevant

GeneCentric Promotes Michael Milburn to CEO & President

Four months after joining GeneCentric as chief scientific officer, Michael Milburn has been promoted to CEO and president of the Durham, NC, company. He succeeds founder, CEO, and president Myla Lai-Goldman, who is taking on the newly created role of executive chairperson of the board of directors. GeneCentric develops tests that match a cancer drug […]


Relevant

GeneCentric Therapeutics Appoints Michael V. Milburn, PhD, Chief Scientific Officer

GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Scientific Officer (CSO). Dr. Milburn, who joins GeneCentric from Metabolon, Inc. where he was CSO, has more than 25 years of R&D successful leadership experience in biotechnology companies and in a major pharmaceutical company. “Michael bring...

GeneCentric Therapeutics Appoints Michael V. Milburn, PhD, President and Chief Executive Officer

CEO Dr. Myla Lai-Goldman named Executive Chairperson GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Executive Officer and President, and he will join GeneCentric’s Board of Directors. Dr. Myla Lai-Goldman, founder, current CEO and President, will assume the newly-created role of Executive Chairpers...


GeneCentric Therapeutics Enters Bladder Cancer Research Collaboration with University of North Carolina

Focus is on advancing cancer subtypes to predict disease progression and pursuing immune-biology related drug response biomarkers GeneCentric Therapeutics, Inc. today announced that it has entered into a research collaboration with the University of North Carolina at Chapel Hill (UNC) to assess patient response to immunotherapeutic drugs such as PD-1 a...

GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North Carolina

Company will develop Pancreatic Cancer Profiler based on technology to identify drug responders for therapeutic development GeneCentric Therapeutics, Inc. today announced that the company has acquired an exclusive license from the University of North Carolina at Chapel Hill (UNC) to technology for subtyping Pancreatic Ductal Adenocarcinoma (PDAC). The ...

Roche’s Genentech agrees to buy Jecure Therapeutics

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CEO The post Roche’s Genentech agrees to buy Jecure Therapeutics appeared first on Pharmaceutical Business review.

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific The post HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics appeared first on Pharma Business review.

Indalo Therapeutics Names Robert Jacks President & CEO

Indalo Therapeutics has appointed Robert Jacks to serve as president and CEO. Jacks was most recently president and chief financial officer of Symbiomix Therapeutics, which was acquired by Lupin in 2017. Indalo was formed by the 2016 merger of Antegrin Therapeutics and Cascadia Therapeutics. The Cambridge, MA-based company’s lead drug candidate, IDL-2965, is expected to […]

Probably Relevant

Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics appeared first on Drug Development Technology.

Dermatology start-up Hoth Therapeutics files for IPO

Hoth Therapeutics Inc. (technology that creates a topical agent from existing therapeutics to treat skin diseases) filed for ...

HiFiBio acquires H-Immune Therapeutics

HiFiBio Therapeutics acquired French biotech H-Immune Therapeutics, a privately held firm developing immuno-oncology therapie...

SMi Group announces the 10th Annual RNA Therapeutics Conference

20 - 21 February 2019, London, UK. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

e-therapeutics, Novo Nordisk enter into research collaboration deal

Under the agreement, the two companies will use e-therapeutics’ network-driven drug discovery platform for the identification of new therapeutics approaches to treat Type 2 diabetes, which currently accounts The post e-therapeutics, Novo Nordisk enter into research collaboration deal appeared first on Pharmaceutical Business review.

Summit Therapeutics plc: Summit Therapeutics to Present at the Canaccord Genuity Growth Conference

Summit Therapeutics plc('Summit', or the 'Company')Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceOxford, UK, and Cambridge, MA, US, 6 August 2018 - Summit Therapeutics p...

PTC Therapeutics to commercialise Akcea’s two rare disease drugs

Ionis Pharmaceuticals affiliate Akcea Therapeutics has signed an agreement with biopharmaceutical company PTC Therapeutics for the commercialisation of its rare...Read More... The post PTC Therapeutics to commercialise Akcea’s two rare disease drugs appeared first on Pharmaceutical Technology.

Abeona Therapeutics Inc.: Abeona Therapeutics präsentiert auf dem WORLDSymposium neue unterstützende Daten für neuartige Gentherapien

NEW YORK und CLEVELAND, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein führendes, in der klinischen Erprobung tätiges Biopharmaunternehmen, das sich auf die Entwickl...

From Parkinson’s to asthma: opportunities for microbiome-based therapeutics

On September 5, speakers at the Microbiome Therapeutics US conference shed light on the future of microbiome therapeutics, which is...Read More... The post From Parkinson’s to asthma: opportunities for microbiome-based therapeutics appeared first on Pharmaceutical Technology.

Abeona Therapeutics Inc.: Abeona Therapeutics ernennt Dr. João Siffert zum Leiter der Forschungs- und Entwicklungsabteilung sowie zum Chief Medical Officer

NEW YORK und CLEVELAND (USA), Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein führendes in der klinischen Erprobung tätiges Biopharma unternehmen, das sich auf die En...

Orchard Therapeutics Limited: Orchard Therapeutics Appoints Industry Veteran Alicia Secor to its Board of Directors

BOSTON and LONDON, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with s...

Abeona Therapeutics Inc.: Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer

NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene thera...

Abeona Therapeutics Inc.: Abeona Therapeutics gibt Finanzergebnisse und Geschäftserfolge des dritten Quartals 2018 bekannt

Telefonkonferenz für Anleger am Montag, 12. November, um 10.00 Uhr ET (amerikanische Ostküstenzeit) NEW YORK und CLEVELAND, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ: ABEO)...

4D Molecular Therapeutics Scores $90 Million in Series B Funding

4D Molecular Therapeutics snagged $90 million in a Series B financing round. The company intends to use the funds to advance its Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics.

Spark Therapeutics, Inc.: Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

PHILADELPHIA, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...

Tusk Therapeutics Ltd: Tusk Therapeutics to be acquired by Roche

Tusk Therapeutics to be acquired by Roche Stevenage, United Kingdom - September 28th 2018: Tusk Therapeutics Ltd ("Tusk") was today acquired by Roche. Tusk has developed an antibody with a novel m...

Abeona Therapeutics Inc.: Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights

Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biophar...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks